CARsgen Therapeutics Widens Loss in 2024

MT Newswires Live

03-19

CARsgen Therapeutics (HKG:2171) widened its attributable loss for the year 2024 to 798.1 million yuan from 747.8 million yuan in the year-ago period, a Tuesday filing with the Hong Kong bourse stated.

Loss per share was 1.44 yuan, up from 1.34 yuan in the corresponding period of the last fiscal year.

Revenue for the year stood at 39.4 million yuan, while the company recorded no revenue in 2023.

The biopharmaceutical company attributed the widened loss mainly to an increase in other net losses.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2520974402"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2520974402\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2520974402?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-19 17:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2520974402","market":"nz","top_or_hot":-1,"title":"CARsgen Therapeutics Widens Loss in 2024","media":"MT Newswires Live","content":"<html><body><p> CARsgen <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (HKG:2171) widened its attributable loss for the year 2024 to 798.1 million yuan from 747.8 million yuan in the year-ago period, a Tuesday filing with the Hong Kong bourse stated.</p><p>Loss per share was 1.44 yuan, up from 1.34 yuan in the corresponding period of the last fiscal year.</p><p>Revenue for the year stood at 39.4 million yuan, while the company recorded no revenue in 2023.</p><p>The biopharmaceutical company attributed the widened loss mainly to an increase in other net losses.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CARsgen Therapeutics Widens Loss in 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCARsgen Therapeutics Widens Loss in 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-19 17:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> CARsgen <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (HKG:2171) widened its attributable loss for the year 2024 to 798.1 million yuan from 747.8 million yuan in the year-ago period, a Tuesday filing with the Hong Kong bourse stated.</p><p>Loss per share was 1.44 yuan, up from 1.34 yuan in the corresponding period of the last fiscal year.</p><p>Revenue for the year stood at 39.4 million yuan, while the company recorded no revenue in 2023.</p><p>The biopharmaceutical company attributed the widened loss mainly to an increase in other net losses.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02171","symbol_name":"科济药业-B","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2520974402","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2520974402","pubTimestamp":1742378094,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"CARsgen Therapeutics  widened its attributable loss for the year 2024 to 798.1 million yuan from 747.8 million yuan in the year-ago period, a Tuesday filing with the Hong Kong bourse stated.Loss per share was 1.44 yuan, up from 1.34 yuan in the corresponding period of the last fiscal year.Revenue for the year stood at 39.4 million yuan, while the company recorded no revenue in 2023.The biopharmaceutical company attributed the widened loss mainly to an increase in other net losses.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02171":"科济药业-B","BK1587":"次新股","LENZ":"Therapeutics","BK1585":"昨日强势股","BK1161":"生物科技","BK4139":"生物科技","BK1574":"生物医药B类股"},"translate_title":"科济康治疗2024年亏损扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":0.9,"LENZ":1},"content_text":"CARsgen Therapeutics (HKG:2171) widened its attributable loss for the year 2024 to 798.1 million yuan from 747.8 million yuan in the year-ago period, a Tuesday filing with the Hong Kong bourse stated.Loss per share was 1.44 yuan, up from 1.34 yuan in the corresponding period of the last fiscal year.Revenue for the year stood at 39.4 million yuan, while the company recorded no revenue in 2023.The biopharmaceutical company attributed the widened loss mainly to an increase in other net losses.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}